AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Oppenheimer Upgrades AngioDynamics (ANGO) to Outperform
April 5, 2024 7:02 AM EDTOppenheimer analyst Steven M. Lichtman upgraded AngioDynamics (NASDAQ: ANGO) from Perform to Outperform with a price target of $12.00.
The analyst comments "We are upgrading ANGO shares from Perform to Outperform with a $12 PT based on the following: 1) Yesterday's earlier than expected FDA approval... More
